10-HYDROXYWARFARIN

Suppliers

Names

[ CAS No. ]:
83219-99-2

[ Name ]:
10-HYDROXYWARFARIN

[Synonym ]:
10-Hydroxywarfarin

Chemical & Physical Properties

[ Density]:
1.388 g/cm3

[ Boiling Point ]:
509.2ºC at 760 mmHg

[ Melting Point ]:
183-185ºC

[ Molecular Formula ]:
C19H16O5

[ Molecular Weight ]:
324.32700

[ Flash Point ]:
185ºC

[ Exact Mass ]:
324.10000

[ PSA ]:
87.74000

[ LogP ]:
2.58040

[ Index of Refraction ]:
1.656

MSDS

Click to get detail MSDS

Safety Information

[ Symbol ]:

GHS05, GHS06

[ Signal Word ]:
Danger

[ Hazard Statements ]:
H300-H318

[ Precautionary Statements ]:
P264-P280-P301 + P310-P305 + P351 + P338

[ Personal Protective Equipment ]:
Eyeshields;Faceshields;Gloves;type P2 (EN 143) respirator cartridges

[ Hazard Codes ]:
T: Toxic;

[ Risk Phrases ]:
25-41

[ Safety Phrases ]:
26-39-45

[ RIDADR ]:
UN 2811 6

Articles

Investigation of two-dimensional high performance liquid chromatography approaches for reversed phase resolution of warfarin and hydroxywarfarin isomers.

J. Chromatogr. A. 1363 , 200-6, (2014)

Several offline and online 2D HPLC methods were investigated for the reversed phase resolution of a complex mixture of closely related warfarin and hydroxywarfarin isomers. By combining reversed phase...

Hydroxywarfarin metabolites potently inhibit CYP2C9 metabolism of S-warfarin.

Chem. Res. Toxicol. 23(5) , 939-45, (2010)

Coumadin (R/S-warfarin) anticoagulant therapy poses a risk to over 50 million Americans, in part due to interpersonal variation in drug metabolism. Consequently, it is important to understand how meta...

Contribution of three CYP3A isoforms to metabolism of R- and S-warfarin.

Drug Metab. Lett. 4(4) , 213-9, (2010)

Effective coumadin (R/S-warfarin) therapy is complicated by inter-individual variability in metabolism. Recent studies have demonstrated that CYP3A isoforms likely contribute to patient responses and ...


More Articles

Related Compounds

  • 10-BROMO-2,3-DIMETHYLANTHRACENE
  • 10,11-dehydro-2-acetoxytrimipramine
  • 10-cyclohexyl-10H-anthracen-9-one
  • 10,12-Pentadecadien-1-ol
  • 10-[4-methoxy-1-(4-methoxyphenyl)sulfonylindol-3-yl]decan-1-ol
  • 10-(2-dimethylaminoethyl)-10,11-dihydrospiro[dibenzo[a,d]cyclohepten-5,2'-oxirane]
  • 2-(((3-Bromothiophen-2-yl)methyl)(cyclopentyl)amino)acetamide
  • N-{3-[(2,3-dihydro-1H-inden-1-yl)(prop-2-yn-1-yl)amino]propyl}methanesulfonamide
  • 5-{[(2,3-dihydro-1H-inden-1-yl)(prop-2-yn-1-yl)amino]methyl}-N-(4-methoxyphenyl)-1,3,4-thiadiazole-2-carboxamide
  • 2-[[2-[(1-Cyanocyclopentyl)amino]-2-oxoethyl]amino]-N,2-diphenylacetamide
  • N-{1-benzyl-3-[(4-methoxyphenyl)sulfonyl]-4,5-dimethyl-1H-pyrrol-2-yl}propanamide
  • C16H14N6O4S4
  • N-methyl-N,3-diphenyl-5,6-dihydro-1,4-oxathiine-2-carboxamide
  • 3-(7-methoxy-4-methyl-2-oxo-2H-chromen-6-yl)-N-(1,3-thiazol-2-yl)propanamide
  • 4-methoxy-N~2~-{3-[(4-methyl-1,3-thiazol-2-yl)amino]-3-oxopropyl}-1H-indole-2-carboxamide
  • N-[4-(1H-1,2,4-triazol-1-ylmethyl)phenyl]-1,3-benzothiazole-6-carboxamide
The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.